Posted by Michael Wonder on 30 May 2024
Vyluma announces marketing authorisation application validation for the European Union
29 May 2024 - Vyluma announced today that the EMA has validated the marketing authorisation application for its lead compound, NVK002.
The application is confirmed to be eligible for a paediatric use marketing authorisation, providing 10 years of data exclusivity and marketing protection upon product approval.
